Patient and physician satisfaction in an observational study with methyl aminolevulinate daylight photodynamic therapy in the treatment of multiple actinic keratoses of the face and scalp in six European countries.

Fargnoli, M C; Ibbotson, S H; Hunger, Robert; Rostain, G; Gaastra, M T W; Eibenschutz, L; Cantisani, C; Venema, A W; Medina, S; Kerrouche, N; Pérez-Garcia, B (2018). Patient and physician satisfaction in an observational study with methyl aminolevulinate daylight photodynamic therapy in the treatment of multiple actinic keratoses of the face and scalp in six European countries. Journal of the European Academy of Dermatology and Venereology, 32(5), pp. 757-762. Blackwell 10.1111/jdv.14691

[img] Text
Fargnoli_et_al-2017-Journal_of_the_European_Academy_of_Dermatology_and_Venereology.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (189kB) | Request a copy

BACKGROUND Guidelines recommend treating actinic keratoses (AKs) as they are recognized as precursors of invasive squamous cell carcinoma. OBJECTIVE The objective of this study was to collect real-world clinical data on the use of methyl aminolevulinate daylight photodynamic therapy (MAL DL-PDT) for the treatment of face and scalp AK in Europe. METHODS A prospective, multicenter, non-interventional study was conducted in six European countries in patients receiving a single treatment of MAL DL-PDT for face and/or scalp AK. Patient-reported outcomes were assessed by patient questionnaires at baseline and at 3 months after treatment, efficacy was assessed at 3 months using a 6-point global improvement scale, and adverse events (AE) were recorded at each visit. RESULTS Overall, 325 patients were enrolled from 52 investigational centres, 314 of whom attended the 3-month visit. Most patients had multiple lesions (58.4% had >10 lesions) with lesions mainly located on the scalp (60.0%) and/or forehead (54.2%). AKs were predominantly grade I (39.4%) or grade II (33.2%), and 10.5% of patients had grade III lesions. The proportions of patients and physicians that were overall satisfied to very satisfied with the MAL DL-PDT treatment were 80.4% and 90.3%, respectively. The vast majority of patients (90.0%) would consider using MAL DL-PDT again if needed. Physician-assessed efficacy at 3 months was at least much improved in 83.5% of patients, with 45.9% of patients requiring no retreatment. Related AEs were reported in 15% of patients. CONCLUSION Use of MAL DL-PDT for multiple face and/or scalp AKs resulted in high levels of patient and physician satisfaction in clinical practice in Europe, reflecting the good efficacy and high tolerability of this convenient procedure.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Hunger, Robert

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0926-9959

Publisher:

Blackwell

Language:

English

Submitter:

Sandra Nyffenegger

Date Deposited:

05 Mar 2018 16:08

Last Modified:

21 Apr 2018 01:31

Publisher DOI:

10.1111/jdv.14691

PubMed ID:

29136306

BORIS DOI:

10.7892/boris.110230

URI:

https://boris.unibe.ch/id/eprint/110230

Actions (login required)

Edit item Edit item
Provide Feedback